Chinese-owned biotech Thousand Oaks Biopharmaceuticals announced that it had netted $45 million in a Series A funding round, led by New Alliance Capital, Addor Capital, and Tenyall & Sumin. With the funds, the company said it plans to build a large-scale cell culture media manufacturing facility outside Shanghai. “This round of financing allows us to…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
